265 related articles for article (PubMed ID: 34579786)
1. Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial.
Barnabas RV; Brown ER; Onono M; Bukusi EA; Njoroge B; Winer RL; Donnell D; Galloway D; Cherne S; Heller K; Leingang H; Morrison S; Rechkina E; McClelland RS; Baeten JM; Celum C; Mugo N;
Trials; 2021 Sep; 22(1):661. PubMed ID: 34579786
[TBL] [Abstract][Full Text] [Related]
2. Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose in young women aged 15-20 years in Kenya (KEN SHE): an immunobridging analysis of randomised controlled trials.
Baisley K; Kemp TJ; Mugo NR; Whitworth H; Onono MA; Njoroge B; Indangasi J; Bukusi EA; Prabhu PR; Mutani P; Galloway DA; Mwanzalime D; Kapiga S; Lacey CJ; Hayes RJ; Changalucha J; Pinto LA; Barnabas RV; Watson-Jones D
Lancet Glob Health; 2024 Mar; 12(3):e491-e499. PubMed ID: 38365419
[TBL] [Abstract][Full Text] [Related]
3. Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results.
Barnabas RV; Brown ER; Onono MA; Bukusi EA; Njoroge B; Winer RL; Galloway DA; Pinder LF; Donnell D; N Wakhungu I; Biwott C; Kimanthi S; Heller KB; Kanjilal DG; Pacella D; Morrison S; A Rechkina E; L Cherne S; Schaafsma TT; McClelland RS; Celum C; Baeten JM; Mugo NR;
Nat Med; 2023 Dec; 29(12):3224-3232. PubMed ID: 38049621
[TBL] [Abstract][Full Text] [Related]
4. A dose-reduction HPV vaccine immunobridging trial of two HPV vaccines among adolescent girls in Tanzania (the DoRIS trial) - Study protocol for a randomised controlled trial.
Baisley KJ; Whitworth HS; Changalucha J; Pinto L; Dillner J; Kapiga S; de Sanjosé S; Mayaud P; Hayes RJ; Lacey CJ; Watson-Jones D
Contemp Clin Trials; 2021 Feb; 101():106266. PubMed ID: 33421649
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial.
Porras C; Sampson JN; Herrero R; Gail MH; Cortés B; Hildesheim A; Cyr J; Romero B; Schiller JT; Montero C; Pinto LA; Schussler J; Coronado K; Sierra MS; Kim JJ; Torres CM; Carvajal L; Wagner S; Campos NG; Ocampo R; Kemp TJ; Zuniga M; Lowy DR; Avila C; Chanock S; Castrillo A; Estrada Y; Barrientos G; Monge C; Oconitrillo MY; Kreimer AR
Vaccine; 2022 Jan; 40(1):76-88. PubMed ID: 34857420
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of single-dose HPV vaccination among young African women.
Barnabas RV; Brown ER; Onono MA; Bukusi EA; Njoroge B; Winer RL; Galloway DA; Pinder LF; Donnell D; Wakhungu I; Congo O; Biwott C; Kimanthi S; Oluoch L; Heller KB; Leingang H; Morrison S; Rechkina E; Cherne S; Schaafsma TT; McClelland RS; Celum C; Baeten JM; Mugo N
NEJM Evid; 2022 Jun; 1(5):EVIDoa2100056. PubMed ID: 35693874
[TBL] [Abstract][Full Text] [Related]
7. Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial.
Baisley K; Kemp TJ; Kreimer AR; Basu P; Changalucha J; Hildesheim A; Porras C; Whitworth H; Herrero R; Lacey CJ; Schiller JT; Lucas E; Mutani P; Dillner J; Indangasi J; Muwonge R; Hayes RJ; Pinto LA; Watson-Jones D
Lancet Glob Health; 2022 Oct; 10(10):e1485-e1493. PubMed ID: 36113532
[TBL] [Abstract][Full Text] [Related]
8. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study.
Sankaranarayanan R; Joshi S; Muwonge R; Esmy PO; Basu P; Prabhu P; Bhatla N; Nene BM; Shaw J; Poli URR; Verma Y; Zomawia E; Pimple S; Tommasino M; Pawlita M; Gheit T; Waterboer T; Sehr P; Pillai MR;
Vaccine; 2018 Aug; 36(32 Pt A):4783-4791. PubMed ID: 29551226
[TBL] [Abstract][Full Text] [Related]
9. A prospective, single-arm, open-label, non-randomized, phase IIa trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9-11 year-old girls and boys - clinical protocol.
Zeng Y; Moscicki AB; Sahasrabuddhe VV; Garcia F; Woo H; Hsu CH; Szabo E; Dimond E; Vanzzini S; Mondragon A; Butler V; DeRose H; Chow HS
BMC Cancer; 2019 Apr; 19(1):290. PubMed ID: 30935375
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.
Dobson SR; McNeil S; Dionne M; Dawar M; Ogilvie G; Krajden M; Sauvageau C; Scheifele DW; Kollmann TR; Halperin SA; Langley JM; Bettinger JA; Singer J; Money D; Miller D; Naus M; Marra F; Young E
JAMA; 2013 May; 309(17):1793-802. PubMed ID: 23632723
[TBL] [Abstract][Full Text] [Related]
11. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study.
Basu P; Malvi SG; Joshi S; Bhatla N; Muwonge R; Lucas E; Verma Y; Esmy PO; Poli URR; Shah A; Zomawia E; Pimple S; Jayant K; Hingmire S; Chiwate A; Divate U; Vashist S; Mishra G; Jadhav R; Siddiqi M; Sankaran S; Prabhu PR; Kannan TPRA; Varghese R; Shastri SS; Anantharaman D; Gheit T; Tommasino M; Sauvaget C; Pillai MR; Sankaranarayanan R
Lancet Oncol; 2021 Nov; 22(11):1518-1529. PubMed ID: 34634254
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
[TBL] [Abstract][Full Text] [Related]
13. The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan.
Chou HH; Chang SC; Sukarom I; Saxena K; Pavelyev A; Wu YH; Chang CJ
Value Health Reg Issues; 2022 Nov; 32():79-87. PubMed ID: 36116338
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial.
Watson-Jones D; Changalucha J; Whitworth H; Pinto L; Mutani P; Indangasi J; Kemp T; Hashim R; Kamala B; Wiggins R; Songoro T; Connor N; Mbwanji G; Pavon MA; Lowe B; Mmbando D; Kapiga S; Mayaud P; de SanJosé S; Dillner J; Hayes RJ; Lacey CJ; Baisley K
Lancet Glob Health; 2022 Oct; 10(10):e1473-e1484. PubMed ID: 36113531
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness of pay-it-forward in addressing HPV vaccine delay and increasing uptake among 15-18-year-old adolescent girls compared to user-paid vaccination: a study protocol for a two-arm randomized controlled trial in China.
Li Y; Qin C; Qiu S; He Y; Pang L; Xu X; Yim VW; Tang S; Du H; Gong W; Yang F; Tucker JD; Tang W; Wang Y; Lin L; Jit M; Song W; Li C; Smith J; Li J; Wu D
BMC Public Health; 2023 Jan; 23(1):48. PubMed ID: 36609267
[TBL] [Abstract][Full Text] [Related]
16. Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis.
Tay SK; Hsu TY; Pavelyev A; Walia A; Kulkarni AS
BJOG; 2018 Mar; 125(4):478-486. PubMed ID: 29266694
[TBL] [Abstract][Full Text] [Related]
17. Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries.
Burger EA; Portnoy A; Campos NG; Sy S; Regan C; Kim JJ
Int J Cancer; 2021 Feb; 148(4):932-940. PubMed ID: 32706907
[TBL] [Abstract][Full Text] [Related]
18. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
Donken R; Knol MJ; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE
J Infect; 2015 Jul; 71(1):61-73. PubMed ID: 25709084
[TBL] [Abstract][Full Text] [Related]
19. Design and statistical considerations for studies evaluating the efficacy of a single dose of the human papillomavirus (HPV) vaccine.
Sampson JN; Hildesheim A; Herrero R; Gonzalez P; Kreimer AR; Gail MH
Contemp Clin Trials; 2018 May; 68():35-44. PubMed ID: 29474934
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
